Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

19.00 +0.60 (+3.26%)
Streaming Delayed Price Updated: 2:09 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PureTech Health plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
From PureTech Health plc
Via Business Wire
PureTech Health: Notice of Half-Yearly Results
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
From PureTech Health plc
Via Business Wire
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
From PureTech Health plc
Via Business Wire
PureTech Announces Leadership Transition
From PureTech Health plc
Via Business Wire
PureTech Announces Board Change
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
From PureTech Health plc
Via Business Wire
PureTech Health: Results of Annual General Meeting
From PureTech Health plc
Via Business Wire
PureTech to Present at the Jefferies Global Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
From PureTech
Via Business Wire
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
From PureTech Health plc
Via Business Wire
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
From PureTech Health plc
Via Business Wire
PureTech Announces Annual Results for Year Ended December 31, 2024
From PureTech Health plc
Via Business Wire
PureTech Health: Notice of Results
From PureTech Health plc
Via Business Wire
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
From PureTech Health plc
Via Business Wire
PureTech Health plc Statement Regarding Press Speculation
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
From PureTech Health plc
Via Business Wire
PureTech to Present at the Leerink Partners Global Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
From PureTech Health plc
Via Business Wire
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
From PureTech Health plc
Via Business Wire
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
From PureTech Health plc
Via Business Wire
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Appoints UBS as UK Corporate Broker
From PureTech Health plc
Via Business Wire
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
From PureTech Health plc
Via Business Wire
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
From PureTech Health plc
Via Business Wire
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.